Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition
Video navigation menu
- Residual risk in patients with ACS and diabetes 0:31
- Inflammatory residual risk post ACS in diabetic patients 2:13
- Apabetalone may target several residual risk factors 3:38
- Clinical trials with apabetalone 4:12
This lecture held by prof. Ray was part of an accredited symposium "Epigenetics: A new pathway to tackle residual risk?" held during ESC Congress 2019 in Paris, France.
Prof. Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.